The US IPO market produced seven IPOs in January 2013—the busiest start to the year since 2006. Buoyed by the $2.2 billion IPO of Pfizer’s animal health unit Zoetis, gross proceeds in January were $3.3 billion—the highest January figure since 2000. The month included IPOs by well-established companies with proven revenue and profitability as well as a trio of biotech offerings.
The average first-day gain for January’s IPOs was 18% compared to 16% for all IPOs in 2012. Norwegian Cruise Line, Bright Horizons and Zoetis enjoyed first-day gains of 30%, 29% and 19%, respectively—these gains were all the more striking because each offering was priced above the range. There were no “broken” IPOs (IPOs whose stock closes below the offering price on their opening day) in the month.
With offerings by KaloBios Pharmaceuticals, LipoScience and Stemline Therapeutics during the last week of January, the biotech IPO market began the year with a solid start. LipoScience and Stemline rose 16% and 18%, respectively, in first-day trading while KaloBios was flat. Each of these IPOs priced at the bottom of the range.
The remaining January IPO was by Starwood-backed homebuilder TRI Pointe Homes, which saw a 12% first-day gain after pricing above the range.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
On November 1, 2016, the SEC's DERA published additional economic analysis setting forth the methodology used to analyze certain comments received on the SEC's proposed rule regarding the use of derivatives by registered funds and business development companies.
The Consumer Financial Protection Bureau ("CFPB"), in its most recent set of Supervisory Highlights, provides a bit of insight into how it interprets its Ability to Repay Rule for loans that are not Qualified Mortgages ("QMs").
The US District Court for the Central District of California (the Central District) has recently rendered two decisions with "true lender" implications of potential significance to the marketplace lending industry...
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).